CAIX-Specific CAR T-Cells Overcoming MHC Downregulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapies for cancer, such as renal cell carcinoma, face challenges due to tumor immune escape mechanisms, including downregulation of MHC class I-restricted antigen presentation, energy induction, and immunosuppressive cytokine secretion, which hinder effective targeting of carbonic anhydrase IX (CAIX) expressing tumors.
Innovation Solution
Development of chimeric antigen receptors (CARs) specific for carbonic anhydrase IX (CAIX) that combine an extracellular antigen-binding domain from a CAIX-specific antibody with intracellular signaling domains, including CD3 zeta and costimulatory molecules like CD28, to enhance T-cell targeting and activation of CAIX-positive cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional immunotherapies (TCR-modified T cells) are used to target CAIX-positive tumors, then tumor targeting capability is achieved, but anti-tumor activity is hampered by tumor immune escape mechanisms including MHC class I downregulation, induced anergy, and immunosuppressive cytokine secretion
Solution Approach 1:
The patent segments the T-cell receptor system into a chimeric antigen receptor that separates antigen recognition (via antibody variable domains) from signaling functions. This allows the CAR to target CAIX directly without requiring MHC class I presentation, thereby overcoming tumor immune escape mechanisms that downregulate MHC molecules.
Solution Approach 2:
The patent introduces an intermediary antibody-based recognition system (CAIX-specific antibody variable domains) that mediates tumor targeting independently of the MHC class I-restricted antigen presentation pathway. This intermediary mechanism bypasses the tumor's ability to evade T-cell recognition through MHC downregulation.
2Measurement precision
If TCR-modified T cells are used for tumor targeting, then antigen-specific recognition is achieved, but costimulatory molecule loss on tumors leads to induced anergy
Solution Approach 1:
The patent merges multiple functional domains into a single chimeric antigen receptor molecule: the antigen-binding domain (from CAIX-specific antibodies), transmembrane domain, and intracellular signaling domains including costimulatory motifs (CD28, 4-1BB, OX40). This unified structure ensures that both antigen recognition and costimulatory signaling are delivered simultaneously to the T cell, preventing anergy induction.
Solution Approach 2:
The CAR construct functions as a composite molecular entity combining elements from different sources: antibody variable domains for antigen binding, T-cell receptor signaling domains for activation, and costimulatory molecule domains for enhanced T-cell survival and proliferation. This composite structure overcomes the limitations of natural T-cell recognition systems.
3Reliability
If CARs with multiple costimulatory domains are constructed to enhance T-cell activation, then cytotoxic potency and clonal expansion are increased, but receptor structure and signaling complexity increase
Solution Approach 1:
The patent segments the CAR into modular functional domains that can be independently optimized and combined: antigen-binding domain, transmembrane domain, intracellular signaling domain with ITAMs, and costimulatory domains. This modular architecture allows systematic construction of CARs with different costimulatory configurations (single or multiple domains) to achieve desired potency while managing complexity.
Data Source
AI summary
The present invention provides chimeric antigen receptor cells specific for carbonic anhydrase IX (CAIX) and methods of using same for treatment of CAIX expressing cancers such as renal cell carcinoma.